One in five people will develop dementia. Keep your body and brain healthy. Learn more about the facts and figures of Alzheimer’s disease: https://bit.ly/ALZDaware
Related posts:
- FDA Advisory Panel meeting held to consider potential approval of donanemab Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND....
- MIND Matters | Quarterly Newsletter | Spring 2024 Message from the Director Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of exciting updates about the impact UCI MIND investigators are having in the field. On the cover, post-doctoral fellow Dr. Claire...
- Celebrating Hispanic Heritage Month: Honoring Our Commitment to Alzheimer’s Research in Hispanic and Latino Communities This Hispanic Heritage Month, we proudly recognize the invaluable contributions of our faculty, staff, community partners, and supporters who are dedicated to addressing Alzheimer’s disease and related dementias in the Hispanic and Latino communities. Our mission to advance Alzheimer’s research is strengthened by the passion and collaboration of those working...
